| HOME >> BIOLOGY >> TECHNOLOGY |
% of % of
product product
2008 sales 2007 sales
$m $m
_________ _________ _________ _________
SG&A (US GAAP) 428.8 61% 280.6 56%
Costs associated with the
introduction of a new
holding company
(6.6) -
Amortization (31.0) (17.6)
Impairment of intangible (90.4) -
assets
Depreciation (11.2) (9.9)
_________ _________
SG&A (Non GAAP) 289.6 41% 253.1 50%
_________ _________
SG&A expenses increased to $428.8 million for the three months to June 30, 2008 from $280.6 million in the corresponding period in 2007. Excluding an intangible asset impairment charge of $90.4 million in respect of DYNEPO, amortization of intangible assets (increased due to VYVANSE, launched July 2007), costs associated with the introduction of the new holding company and depreciation costs (see reconciliation table above), SG&A expenditure increased by $36.5 million to $289.6 million.
Excluding these items, SG&A decreased as a percentage of product sales to 41% (2007: 50%) reflecting the sales impact in the three months to June 30, 2008 of the successful launches of VYVANSE, LIALDA/MEZAVANT and ELAPRASE.
Other increases in SG&A expens
'/>"/>
| SOURCE Shire Ltd Copyright©2008 PR Newswire. All rights reserved |